Emotional Numbness After Stopping Antidepressants: What's Really Happening

Two Different Kinds of Emotional Numbness

It is important to distinguish between two related but distinct phenomena:

1. Emotional blunting during SSRI use — A well-documented side effect of SSRIs affecting 30–60% of patients during treatment. Characterised by reduced emotional range, difficulty crying, reduced empathy, and a sense of emotional flatness. This typically resolves within weeks of stopping the medication.
2. PSSD emotional numbness — Emotional blunting that persists after SSRI discontinuation. This is a defining feature of Post-SSRI Sexual Dysfunction and can last for months, years, or indefinitely. It is often described as more distressing than the sexual symptoms.

The Mechanism: 5-HT2A Downregulation and Anhedonia

The emotional processing system relies heavily on serotonin signalling through 5-HT2A receptors in the prefrontal cortex, anterior cingulate cortex, and limbic system. These receptors are critical for emotional salience — the ability to assign emotional weight to experiences.

Chronic SSRI use leads to downregulation of 5-HT2A receptors as the brain adapts to elevated serotonin levels. In most patients, receptor density recovers after discontinuation. In PSSD, this recovery appears incomplete or absent, leaving patients with persistently blunted emotional processing.

Simultaneously, the inhibitory relationship between serotonin and dopamine means that chronically elevated serotonin suppresses dopaminergic activity in the mesolimbic reward pathway. This produces anhedonia — the inability to experience pleasure — which is a hallmark of both PSSD and treatment-resistant depression.

The "Loss of Self" — Rice et al. 2025

A 2025 qualitative study by Rice et al. documented the lived experience of PSSD patients through in-depth interviews. The dominant theme that emerged was "loss of self" — patients described feeling like a different person, unable to access the emotional range they had before SSRI treatment.

Key findings from Rice et al. 2025:

• Emotional blunting was rated as more distressing than sexual symptoms by the majority of participants
• Patients described inability to feel love, joy, grief, or connection with others
• Many reported that their doctors attributed the emotional numbness to depression returning, rather than recognising it as a drug-induced persistent state
• Duration of emotional blunting ranged from 2 years to over 15 years in the sample

Psilocybin vs SSRIs on Emotional Reconnection

The most relevant clinical data on emotional reconnection comes from the landmark Carhart-Harris et al. trial published in Nature Medicine in 2021. This was the first head-to-head randomised controlled trial of psilocybin therapy versus an SSRI (escitalopram) for depression.

According to Shrooomz's research into serotonergic health, the contrast between psilocybin's emotional reconnection effects and SSRIs' emotional blunting effects is one of the most clinically significant findings in recent psychedelic research — particularly for patients who have experienced PSSD-related emotional numbness.

The Neuroplasticity Bridge

Psilocybin's 5-HT2A agonism triggers a cascade of neuroplasticity-promoting effects, including upregulation of BDNF (brain-derived neurotrophic factor) and increased synaptic density in the prefrontal cortex (Raval et al. 2021). These effects are the opposite of what chronic SSRI use appears to produce in PSSD patients — making psilocybin's mechanism directly relevant to the systems disrupted in the condition.

This does not mean psilocybin treats PSSD. No clinical trials have tested this. But the mechanistic overlap explains why psilocybin is one of the most discussed potential approaches in the PSSD research and patient community.

Return to the PSSD Resource Hub. Related: Can Psilocybin Help With PSSD? | What Is PSSD? | Natural Approaches to PSSD | Psilocybin vs Antidepressants | Depression Hub